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KEY POINTS
 A low-caloric diet and a structured exercise program should be recommended for obese
anovulatory women.
 Clomiphene citrate is the initial treatment for most women with ovulatory dysfunction and
unexplained infertility.
 Ovulation induction monitoring may be useful to document ovulation and for the timing of
intercourse or intrauterine insemination.
 Letrozole is an option for women who have failed to ovulate or conceive as well as for
those with thin endometrial lining or bothersome side effects using clomiphene citrate.
 Gonadotropins are second-line agents for anovulation and require close observation
because of the high rates of multiple pregnancies.
 The role of laparoscopy in the evaluation and treatment of ovulatory disorders or unex-
plained infertility is unclear.INFERTILITY AND OVULATORY DYSFUNCTION
With an average monthly fecundity rate of only 20%, human beings are not fertile
compared with other mammals.1 Overall, 10% to 15% of couples have difficulties
conceiving, or conceiving the number of children they want, and many will seek
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Propst & Bates508a disease defined as the failure to conceive after 12 months of regular unprotected
intercourse in a reproductive-aged couple. Beginning the fertility evaluation prior to
one year of infertility is warranted when the woman has known or suspected anovula-
tion or tubal factor, is older than 35 years, or if her partner has a suspected male
factor.2 Infertility affects a large number of couples. National surveys indicate that
11% of nulliparous married women younger than 29 years have nonvoluntary infertility
and that rate increases to 27% of nulliparous married women aged 40 to 44 years.3
Ovulatory dysfunction is one of the major causes of infertility, affecting 25% of
couples with infertility.4 The World Health Organization (WHO) has classified anovula-
tion into 3 categories.5
1. WHO I is anovulation with low gonadotropin levels, sometimes referred to as hypo-
gonadotropic hypogonadism. Women with this form of anovulation have low levels
of endogenous estrogen, do not develop an adequate endometrial lining, and will
usually not bleed when given a progestin challenge to induce progestin withdrawal
bleeding. Clinically, these women will often have a body mass index less than 20
and are involved in high-intensity exercise or have high stress levels. In addition,
they usually do not respond to oral ovulation induction medications because of
hypothalamic-pituitary dysfunction and will usually need injectable gonadotropins
that directly stimulate the ovarian follicles to ovulate.
2. WHO II is anovulation with normal levels of gonadotropins. Women with this type of
anovulation make endogenous estrogen and will usually respond with menstrual
bleeding when given a progestin challenge. Polycystic ovarian syndrome (PCOS)
is an example of this type of ovulatory disorder. Clinically, these women usually
have a functioning hypothalamus and pituitary system and generally respond to
oral ovulation induction medications.
3. WHO III is anovulation with elevated gonadotropins. Women of reproductive age
who have elevated gonadotropins are usually a result of premature ovarian failure,
either caused by unknown causes or caused by ovarian damage from chemo-
therapy, radiation, or surgery. Clinically, these women have limited ovarian follicles
that are not responding to high endogenous follicle-stimulating hormone (FSH)
stimulation. Similarly, they do not respond to additional ovarian stimulation through
fertility medications and usually require third-party reproduction, such as an egg
donor, to conceive.
POLYCYSTIC OVARIAN SYNDROME
Most women with anovulatory infertility have PCOS, and most women with PCOS are
overweight or obese. This combination requires careful attention to the morbidities
associated with obesity and the need for lifestyle intervention with exercise and dietary
changes to achieve weight loss. PCOS prevalence in the population and impact on
reproduction as well as overall health warrants special consideration. PCOS is
covered in depth in the article by Bates and Propst elsewhere in this issue.
UNEXPLAINED INFERTILITY
Approximately 25% of couples will have no identifiable cause for their subfertility
following a routine evaluation.6 The diagnosis of unexplained infertility requires
a normal semen analysis with evidence of tubal patency and ovulation. As one would
surmise, the absences of an abnormal finding does not preclude the presence of an
obstacle to normal reproduction (Table 1). However, exhaustive testing or pursuit of
potential causes of infertility, in most cases, will not increase the efficacy of treatment
Table 1
Assessment of endocrine function in infertility patients
Endocrine System Screened Laboratory Test
Thyroid Thyroid stimulating hormone
Pituitary Prolactin
Androgen excess Total and free testosterone, DHEA-S
Congenital adrenal hyperplasia 17-OH progesterone
Cushing syndrome 24-h urine cortisol or overnight dexamethasone suppression
test
Abbreviations: DHEA-S, Dehydroepiandrosterone Sulfate; 17-OH, 17-hydroxyprogesterone.
Data from Kamath MS, Bhattacharya S. Demographics of infertility and management of unex-
plained infertility. Best Pract Res Clin Obstet Gynaecol 2012 Aug 27. [Epub ahead of print].
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a successful pregnancy in women with unexplained infertility is by definition empiric,
and much controversy surrounds the risk versus benefit of ovulation induction in this
population. The clinician must weigh the potential benefit based on inconclusive data
with the known risk of multiple gestations and other possible negative sequelae of
supraphysiologic estrogen levels.FERTILE WINDOW
There are a limited number of days in a menstrual cycle when a woman is fertile. In
a landmark study that defined the fertility window, investigators looked at the timing
of intercourse in relation to ovulation for 221 couples and evaluated subsequent preg-
nancy rates.7 This study found that the fertile window begins 5 days before ovulation
and ends on the day of ovulation. The highest likelihood of becoming pregnant is from
2 days before ovulation until the day of ovulation, with the pregnancy likelihood of
approximately 35% on those 3 days. In a European study of 770 couples using natural
family planning methods of contraception, 650 couples had intercourse at least once
during the preovulatory period they were supposed to be abstaining, resulting in 433
pregnancies.8 This study also found that the fertile window begins 5 days before
ovulation and ends at ovulation, with the peak fecundity occurring with intercourse
2 days before ovulation. Women are most fertile the 2 days before ovulation and
should be instructed to time intercourse during this period so that sperm are present
in the genital tract before the follicle ovulates and releases the oocyte.OVULATION INDUCTION MONITORING
When using medications for ovulation induction, it is imperative to document ovulation
or lack thereof. Knowing whether or not ovulation has occurred allows not only for
proper timing of intercourse or intrauterine insemination (IUI) but also helps define
the method of therapy for subsequent cycles in the event ovulation does not occur.
Several methods exist to access ovulation ranging from minimal to invasive testing.
1. The presence of regular menses and moliminal symptoms before menses is a sign
that the woman is ovulatory. The luteal phase following ovulation to menses is typi-
cally 14 days, regardless of the length of time between menses. Ovulation typically
occurs on day 10 of a 24-day menstrual cycle, day 14 of a 28-day menstrual cycle,
and day 21 of a 35-day menstrual cycle.
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ovulation.9 The body temperature will increase slightly after ovulation in response
to an increase in endogenous progesterone. The cumbersome nature of monitoring
daily temperatures first thing in the morning and because the temperature increase
will occur only after ovulation and the fertility window is closed make charting basal
body temperature less useful than other ovulation detection methods.
3. Urine luteinizing hormone (LH) detection kits detect the endogenous LH surge that
occurs 36 to 48 hours before ovulation.10 This method seems to be an easy and
reliable method that patients are compliant with. Testing should begin 4 days
before expected ovulation, based on the cycle length. Digital and nondigital ovula-
tion predictor kits are available. The digital kits are more expensive but easier to
interpret and are preferred by volunteers over the nondigital kits.11 Once LH has
been detected in the urine, patients should be instructed to have intercourse that
day and the following day or scheduled for an IUI. Detection of ovulation and proper
timing of intercourse doubled the chances of conception (odds ratio 1.89) in
a cohort of women with no known obstacles to pregnancy.12 This finding raises
the possibility that a subset of unexplained infertility may be caused by poorly timed
intercourse.
4. Luteal serum progesterone levels can also be measured to confirm that ovulation
has occurred. When ovulation has occurred, the midluteal phase serum proges-
terone is greater than 3 ng/mL and preferably greater than 10 ng/mL. Serum
progesterone should be measured approximately 1 week after expected ovulation.
This practice will document ovulation but provides no guidance in the timing of
intercourse or IUI.13
5. For patients that have difficulty detecting ovulation by ovulation predictor kits,
ovarian follicular development can be monitored by ultrasound. When the lead
follicle is 20 mm or more, ovulation can be induced with an injection of human cho-
rionic gonadotropin (hCG). A recent retrospective study found a higher pregnancy
rate when the lead follicle was 23 to 28 mmwhen given hCG.14 Intercourse or an IUI
can be timed for 12 to 36 hours following the hCG injection. Alternatively, the IUI
can be scheduled after detecting ovulation using an LH detection kit. However,
using LH testing results in higher rates of canceled cycles because of a false-
negative rate of approximately 15% with LH testing.15MEDICAL AND SURGICAL TREATMENT OPTIONS
Clomiphene Citrate
A variety of medications can be used to induce ovulation in women with ovulatory
dysfunction. The most common initial ovulation induction medication is clomiphene
citrate (CC), which can be combined with timed intercourse or IUI. CC is a nonsteroidal
triphenylethylene derivative that has both estrogen agonist and antagonist proper-
ties.9 CC was approved for clinical use in 1967 and predominately acts as an estrogen
antagonist. CC binds to the estrogen receptors primarily in the hypothalamus. The
prolonged binding of CC to the estrogen receptors interrupts the negative feedback
of the increasing estrogen level and results in continued production of FSH, which
stimulates follicular growth and maturation.9 It is indicated for use in anovulatory
women with normal thyroid and prolactin and who produce endogenous estrogen.
It is also indicated for the empiric treatment of women with unexplained infertility
when it is most effective when combined with IUI.9
CC is administered orally, beginning 3 to 5 days after the onset of a spontaneous or
progestin-inducedmenses.9 Contrary to traditional practice, a recent study suggested
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a progestin withdrawal had significantly higher conception and live birth rates than
women who took a progestin to induce menses before starting CC.16 Treatment typi-
cally begins with a single 50-mg tablet daily for 5 days. Ovulation usually occurs within
5 to 10 days after the last dose of CC. It is important to confirm ovulation in patients
that are using CC and to continue with the lowest dose that achieves ovulation. There
is no benefit to increasing the dose if patients ovulate but do not get pregnant during
that cycle. If patients remain anovulatory, the dose should be increased. Most patients
that will ovulate on CC will ovulate at the 100-mg dose or less, with decreasing rates of
ovulation at higher doses for patients resistant at the 100-mg dose. The United States
Food and Drug Administration’s maximum recommended dose is 100 mg/d for 5
days; however, some physicians will continue to increase the dose in 50-mg incre-
ments up to 250 mg until ovulation is achieved.9 Some CC-resistant women who
fail to ovulate with a 5-day regimen of 250 mg/d may respond to an 8-day course of
the same dose.17
The use of CC in anovulatory women results in ovulation rates of approximately 75%
and overall pregnancy rates of 50% to 70% of those who ovulate and continue the
medication for up to 12 cycles.18,19 Cycle fecundity is approximately 15% in anovula-
tory women who ovulate in response to CC. Most conceptions occur within the first 6
ovulatory cycles. Most women (88%) who conceive with the assistance of CC do so at
doses of 150 mg or less and 52% conceive at doses of 50 mg.19 If ovulation has not
occurred at 100-mg or 150-mg doses, complimentary or alternative medications for
ovulation induction should be implemented, which is discussed later.
Similar to ovulatory women, the fecundity rate for women using CC decreases with
age. In a large retrospective analysis of 4000 CC cycles with IUI of anovulation and
unexplained infertility, the per-cycle fecundity rates were 10% for women younger
than 35 years but 4% or less for women aged 41 years or older.20
Empiric treatment with CC for couples with unexplained infertility is a first-line
therapy. CC or IUI as individual treatments do not improve the baseline chance of
conception each month (fecundity) compared with historical controls, but the combi-
nation of CC with IUI can double the monthly fecundity rate.21
The incidence of multiple gestations with the use of CC is approximately 8% and
most of these are twins. Triplet or higher-order multiple births are rare but can occur.9
The most common side effect is vasomotor symptoms, which occur in approximately
10% of women taking CC. Less common side effects include mood swings, breast
tenderness, headaches, and nausea. Visual disturbances occur in less than 2% but
occasionally can be permanent, and CC use should be stopped in patients who
have them.
There is not an increase of congenital anomalies or birth defects in the children
conceived by women taking CC. Although some retrospective studies have reported
an increased risk of ovarian cancer, overall there does not seem to be an increase in
the incidence of ovarian or breast cancer in infertile women who have taken CC.22,23
Letrozole
Letrozole is an aromatase inhibitor that blocks the conversion of androgens to estro-
gens. Letrozole is indicated for the treatment of postmenopausal women with
hormone-receptor-positive or unknown breast cancer. However, it is increasingly
being used off label for ovulation induction. Letrozole’s mechanism of action for ovula-
tion induction is thought to be the release of the hypothalamus and the pituitary from
the negative feedback of estrogen (Fig. 1).24 With a lower estradiol level, there is less
negative feedback on the hypothalamus and pituitary and the levels of GnRH and,
Fig. 1. Hypothalamic Pituitary Ovarian Axis and Aromatase Inhibition. IGF, Insulin like
Growth Factor. (From Holzer H, Casper R, Tulandi T. A new era in ovulation induction. Fertil
Steril 2006;85(2):277–84; with permission.)
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ment. Letrozole can be used to stimulate ovulation in women who do not respond
to CC or in women that have side effects with CC, such as uncomfortable vasomotor
symptoms, visual changes, or headaches.25 These side effects are rare in patients
using letrozole for ovulation induction. Some patients will have a thin endometrium
(less than 7 mm) when taking CC. The proliferation of the endometrium is stimulated
by estrogen. Because CC acts as an estrogen antagonist, in some women the endo-
metrial lining is thin, which may reduce implantation. Letrozole does not have the same
antiestrogen effect on the endometrium.26,27 Letrozole can be used in combination of
timed intercourse or IUI.
Letrozole is typically prescribed at a starting dose of 2.5 to 5.0 mg and can be
increased by increments of 2.5 mg.28 The highest commonly used dose is 7.5 mg. It
is given for 5 consecutive days like CC and can be started as early as day 3 of the cycle.
A recent publication reported using letrozole at higher doses, up to 12.5 mg/d, with
high rates of ovulation among patients who did not respond to lower doses.29
The first report of letrozole being used as an ovulation inductionmedicationwas pub-
lished in 2001 and looked at 12womenwho had failed to ovulatewith CC treatment and
an additional 10 women who ovulated on CC but who had an endometrial thickness of
5 mm or less.26 Letrozole 2.5 mg was given for 5 days (day 3 to 7). The rate of ovulation
increased from 44%while taking CC to 75%with letrozole. The endometrial thickness
went from5mmor lesswithCC to amean endometrial thickness of 8mmwith letrozole.
Several studies have looked at letrozole versus CC as a first-line therapy in women
with anovulatory infertility (Table 2).28 Begum and colleagues27 looked at the rate of
ovulation, endometrial thickness, and pregnancy rates between 64 women who failed
to ovulate when taking CC 100 mg. These women were randomly assigned to either
CC 150 mg or letrozole 7.5 mg for 5 days. This study showed higher rates of ovulation
(62.5% vs 37.5%) endometrial thickness, and overall pregnancy rate (40.6% vs
18.8%) in to the letrozole group compared with the CC group.
Table 2
RCTs comparing letrozole versus clomiphene as first line for anovulatory women
S. No. Authors Study Design Treatment Arms Numbers Cycles
Endometrial
Thickness (mm) Ovulation Rates (%) Pregnancy Rates (%)
1 Atay et al,30 Turkey,
2006
RCT Letrozole 2.5 mg vs
clomiphene 100 mg
51 vs 55 8.4  1.8 vs 5.2  1.2 82.4 vs 63.6 21.6 vs 9.1
2 Bayar et al,10 Turkey,
2006
RCT Letrozole 2.5 mg vs
clomiphene 100 mg
99 vs 95 8a vs 8a 65.7 vs 74.7 9.1 vs 7.4
3 Badawy et al,31 Egypt,
2009
RCT Letrozole 5 mg vs
clomiphene 100 mg
540 vs 523 8.1  0.2 vs 9.2  0.7 67.5 vs 70.9 15.1 vs 17.9
Abbreviation: RCT, randomized controlled trial.
a Values represent median.




























Propst & Bates514Atay and colleagues30 performed a randomized controlled trial (RCT) that evaluated
106 women with PCOS to receive either letrozole (2.5 mg) or CC (100 mg) for 5 days.
The ovulation rates (82.4% vs 63.6%) and clinical pregnancy rates (21.6% vs 9.1%)
were significantly higher in the letrozole group. However, in the largest RCT, involving
more than 400 women and 1000 cycles, Badawy and colleagues31 compared letrozole
versus CC for women with PCOS and found similar ovulation (67.5% vs 70.9%) and
pregnancy rates (15.1% vs 17.9%). The investigators concluded that there was no
benefit for letrozole over CC, especially because letrozole is more expensive than CC.
A review of clinicaltrials.gov shows that several trials are underway that evaluate CC
versus letrozole, including 2 by the National Institutes of Child Health and Human
Development’s The Reproductive Medicine Network. The first, Pregnancy in Poly-
cystic Ovarian Syndrome II, is comparing letrozole versus CC for women with
PCOS, whereas the Assessment of Multiple Intrauterine Gestations from Ovarian
Stimulation trial is assessing the risk and benefit of superovulation with letrozole,
CC, or gonadotropins in women with unexplained infertility.
One advantage of letrozole is that it has a lower incidence of multiple pregnancies
when compared with CC or gonadotropins.32 Several years ago, there was some
concern raised about higher rates of birth defects in women conceived after taking
letrozole. An abstract presentation at the American Society for Reproductive Medicine
in 2005 suggested an increased risk of congenital malformation compared with a low-
risk obstetric control group. The manufacturer of letrozole (Novartis) subsequently
sent a warning letter to doctors that letrozole was not to be used as an ovulation induc-
tion medication. However, a succeeding Canadian study of more than 900 infants that
compared the birth defects of infants born to mothers taking letrozole versus CC
found similar rates of defects in the letrozole infants and the CC infants (2.4% vs
4.8%).33 Patients should be informed that letrozole is being prescribed off label so
they can make an informed decision and are not concerned when they read the
package instructions.
Gonadotropins
The administration of exogenous FSH or human menopausal gonadotropin is consid-
ered the second line of therapy for ovulation induction for patients who do not respond
to oral therapy or have been unsuccessful in achieving a pregnancy.34 Gonadotropins
are the first line of treatment of ovulation induction in the WHO I category of hypogo-
nadotropic hypogonadism because patients are not producing adequate levels of FSH
and LH and do not respond to oral medications, such as CC or Letrozole.5
When starting gonadotropins, patients must understand the expense of the medica-
tions as well as the commitment required in monitoring the effects of the medication.
Close monitoring of serum estradiol levels and follicular number and growth by an
experienced physician is mandatory to minimize the risks of high-order multiple preg-
nancies (HOMP). The key is to start with lower dosages of medication, 50 to 100 IU
daily. Clinical judgment is necessary in dosing the medication and adjusting the
dose throughout the cycle according to estradiol levels and follicular growth.
There are significant risks of twins (11%) and high-order multiples (3.0%–4.1%)
when using gonadotropins.35 HOMP are positively related to the use of high doses
of gonadotropin, higher number of 7- to 10-mm preovulatory follicles, and higher
estradiol.36 HOMP are also more common in younger patients. For women aged
younger than 32 years, HOMP was 6% for 3 to 6 follicles and 20% for 7 or more folli-
cles. For women aged 32 to 37 years, HOMP was 5% for 3 to 6 follicles and 12% for 7
or more follicles. HOMP are also most likely to occur in the first gonadotropin treat-
ment cycle and were rare after the second treatment cycle.37
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starting gonadotropins, using low gonadotropin doses, cancellation for more than 3
follicles that are more than 10 to 15 mm. By using a conservative strategy, 5% to
20% of cycles may be canceled but HOMP rates can be less than 2% and pregnancy
rates can average 10% to 20% per cycle.36
Metformin
Metformin is an antihyperglycemic that is widely used off label as an adjunct to ovula-
tion induction or superovulation. The net effect of lowering serum glucose in women
who are anovulatory is a reduction of androgens and potential resumptions in ovula-
tion.38 Although numerous case series and cohort studies have demonstrated a favor-
able impact on pregnancy rates following ovulation induction, randomized trials have
yielded mixed results.39–41 Metformin has not been shown to increase the chances of
a live birth in women with unexplained infertility. The role of metformin in the treatment
of PCOS and ovulation induction is examined at length in the article by Bates and
Propst elsewhere in this issue.
Glucocorticoids and Clomiphene Citrate
In cases of CC resistance in the setting of normal and elevated dehydroepiandroster-
one, daily dexamethasone (0.5–2.0 mg) or prednisone (5 mg) during the follicular
phase have been used adjunctively with CC. The combination of glucocorticoids
and CC has been shown to significantly increase the rate of ovulation and pregnancy
when compared with CC alone in randomized trials.42–44
Oral Contraceptives and Clomiphene Citrate
Two months of oral contraceptive pill treatment before ovulation induction with CC
may improve the observed rate of ovulation and pregnancy.45 Treatment with Oral
Contraceptive Pills (OCPs) is associated with lower levels of testosterone and andros-
tenedione, which probably accounts for the improved ovarian response to CC.
Timed Intercourse Versus IUI
The decision to proceed with timed intercourse or IUI has to do with the quality of the
partner’s semen; the presence of a cervical factor, such as cervical stenosis; and the
previous treatment history of the patient. Semen analyses can vary based on illness,
stress, and recent ejaculations. A long abstinence interval increases the sperm count
but decreases the percent motile and IUI pregnancy rates.46 Higher pregnancy rates
are seen in daily or every-other-day intercourse versus once weekly because the
percentage of normal sperm seems to correlate with the frequency of ejaculations.10
If an abnormal semen analysis is obtained, it is best to repeat it 6 to 8 weeks later.
After 3 cycles of ovulation and timed intercourse, IUI should be recommended.
However, if the total motile sperm count is less than 10 million, in vitro fertilization
or intracytoplasmic sperm injection is the most cost-effective treatment.47
For womenwith anovulation and a partner with a normal semen analysis, timed inter-
course after ovulation induction is the authors’ recommended first-line treatment. For
couples with unexplained infertility, IUI will improve success rates with both CC and
gonadotropins compared with timed intercourse or intracervical insemination.21,48
Laparoscopy
Laparoscopy has become the gold standard for the diagnosis and surgical treatment
of pelvic pathology. However, its role in the evaluation and treatment of infertility has
become less clear with the advent and success of assisted reproductive technologies
Propst & Bates516(ART). Some investigators argue that the diagnosis of unexplained infertility cannot be
made without a surgical or laparoscopy confirmation of normal pelvic anatomy. A
recent trial of diagnostic laparoscopy found pelvic pathology in 83% of women with
a normal routine fertility evaluation who failed to conceive following 3 months of ovula-
tion induction. The investigators also suggested that surgical intervention increased
the chances of pregnancy.49 Others have argued that even in the presence of tubal
occlusion due to prior tubal ligation, adhesions and/or endometriosis, surgical inter-
vention is inferior to ART.50
One possible exception to the purported demise of reproduction surgery can be
found in laparoscopic ovarian drilling (LOD). This use of thermal energy to damage
the ovarian cortex and reduce production of androgen has been recommended as
the second-line therapy for patients with PCOS who are resistant to ovulation induc-
tion.34 Although LOD has a significantly lower risk of multiple pregnancies, the live birth
rate is also lower when compared with ovulation induction agents.51 Nonetheless,
laparoscopy and LOD may play a role in properly selecting women for whom
advanced ovulation induction is not practical or available or for those who wish to
avoid the risk of multiple gestations and/or the use of gonadotropins.
SUMMARY RECOMMENDATIONS
 A low-caloric diet and a structured exercise program should be recommended
for obese anovulatory women. These lifestyle changes can result in weight loss
and spontaneous ovulation.
 CC is the initial treatment for most women with ovulatory dysfunction and unex-
plained infertility. CC should be started at 50 mg for 5 days of the cycle, starting
between the third and fifth day of the cycle. The dose can be increased by 50 mg
if patients do not ovulate but should not be increased if ovulation is occurring.
 Once ovulation induction methods are prescribed, some type of ovulation induc-
tion monitoring should be performed and ovulation should be documented.
 Letrozole is an option for women who have failed to ovulate using CC. It is typi-
cally started at a dosage of 2.5 to 5.0 mg for 5 days of the cycle, starting between
the third and fifth day of the cycle. Letrozole is also beneficial when patients have
an endometrial lining of 6 mm or less on CC or patients have bothersome side
effects on CC.
 Gonadotropins are second-line agents for anovulation. They should be used with
caution because of the high rates of multiple pregnancies and require close
observation of the developing follicular size and number.
 Laparoscopic ovarian diathermy may play a limited role as a second-line inter-
vention for patients with PCOS. Laparoscopy’s role in the evaluation of unex-
plained infertility is controversial.
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